GlassScriptPhysician profile
Jason D Rupp
NPI 1164797270
$4,051.59
in general payments reported to CMS, 2019-2025
20 companies · $856 in 2025
The $856 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $134 · 2021: $1,576 · 2022: $191 · 2023: $342 · 2024: $605 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,802.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $1,565.63 | 2020-2021 | |
| Abbvie INC. | $674.06 | 2022-2025 | Xen Glaucoma Treatment System, Ozurdex |
| Alcon Vision LLC | $357.59 | 2019-2025 | Hydrus Microstent, Clareon, Wavelight Refractive Suite |
| New World Medical,INC. | $342.88 | 2023-2024 | Streamline, Kahook Dual Blade, Clearpath |
| Glaukos Corporation | $298.32 | 2024-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite |
| Johnson & Johnson Surgical Vision, INC. | $140.62 | 2019-2020 | |
| Allergan, INC. | $109.23 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $106.93 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $62.88 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $57.62 | 2020-2021 | |
| Harrow Eye, LLC | $56.69 | 2025 | Iheezo |
| Amgen INC. | $51.66 | 2025 | Tepezza |
| Dompe US, INC. | $40.66 | 2024 | Oxervate |
| Astellas Pharma US INC | $38.76 | 2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $38.33 | 2024 | Syfovre |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $30.68 | 2022-2023 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $26.71 | 2025 | Eylea Hd |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.98 | 2019 | |
| Oyster Point Pharma, INC. | $14.74 | 2024 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $13.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Rupp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.